Typically, at GSK, we design: * To address the

Typically, at GSK, we design:

* To address these challenges and ensure that we could sustainably develop Rukobia, we have invested tens of millions to construct two manufacturing facilities just to make Rukobia.

"Typically, at GSK, we design and build a new facility around a specific product, so we have a specific trigger with a new product coming from R&D or another manufacturing site."

https://www.europeanpharmaceuticalreview.com/...ase-study/

_____

November 2023 Letter:

"We have also successfully transferred our manufacturing technology allowing us to manufacture leronlimab at scale in preparation for clinical trials and potential FDA approval."

I said a few times earlier this year, my bet is we build our own single drug, mfgr'ing plant.

Why no word on the manufacturer yet?
Due to site scoping sites, etc..
?
With expansion potential & want to keep it under wraps for now?

Who knows.

*GSK buys individual indications. *Investigational Sites worldwide.

*Will Build a manufacturing site.

Given the potential significance of LL & LL-PLS, I would not want any manufacturing data, outside of my control.

All Agreements would be supplied from one facility.

Guess for anyone who believes GSK enters the picture, this article adds another good potential twist.

I like seeing Dr. Lataillade understanding mfgr'ing advantages too.

Sticking to my bet:

A 1 drug manufacturing facility.

Shall see....